Snapshot
Biosimilars
Success Stories
Amanda’s Story
Download
Snapshot
Biosimilars
Success Stories
Amanda’s Story
Download

At Navitus, we remain focused on delivering the lowest net cost, so that medications can be more affordable for the people who need them.

As a pharmacist, I’ve seen firsthand the life-changing impact medications can have on patients. I also understand the challenges plans and payers face in delivering sustainable benefits and effective clinical care. Our annual Drug Trend Report confirms that Navitus controlled year-over-year costs for commercial clients and delivered savings that support affordability and access for members.

Sharon Faust, PharmD, MBA, CSP    

Chief Pharmacy Officer  

3.1% utilization trend. 3.8 unit cost trend. 7.0 net total cost PMPM trend. 5.9% net total cost PMPM trend, excluding GLP-1 RAs.

Utilization Trend

Unit Cost Trend

Net Total Cost
PMPM *Trend

Net Total Cost
PMPM Trend
excluding GLP-1s

How Navitus is making a difference

As a company, we support:

  • Clinically appropriate prescribing, utilization and formulary management
  • Generic-first strategies and timely adoption of biosimilars
  • Passing through 100% of negotiated rebates and discounts to our clients
  • Managing specialty costs across both the pharmacy and medical benefit
30% of our clients had negative trend. 89% generic dispensing rate (GDR) for non-specialty medications. 100% pass through of rebates and discounts.

Specialty trend drivers

Increasing: oncology, dermatology 
Decreasing or stable: targeted immunomodulators (TIMs), multiple sclerosis (MS) 

12.3% utilization trend. -4.0% unit cost trend. 7.7% net total cost PMPM trend.

Non-specialty trend drivers

Increasing: diabetes, migraine, antivirals 
Decreasing or stable: attention-deficit/hyperactivity disorder (ADHD)  

3.0% utilization trend. 3.1% Unit cost trend. 6.3% net total cost PMPM trend. 3.5% net total PMPM trend excluding diabetic GLP-1 RAs.

Learn more about these industry shifts in the Drug Trend Report 

Download the report

Learn more about these industry shifts in the Drug Trend Report 

Download the report

Members are more than just numbers to us

Navitus stands out for its commitment to transparency and lowest net cost which has significantly benefited Progressive and its members. From the outset, their 100% pass-through model has ensured that we receive the full value of manufacturer rebates and discounts, directly translating to reduced pharmacy costs […] Overall, Navitus has proven to be a reliable and flexible partner, consistently helping us manage costs while maintaining high-quality care for our members.

Heidi Minter

Data Analyst, Benefits Design & Services, Progressive Insurance

Close to home: A mother’s story

Amanda, Manager of Experiential Learning and Chair of the accredited Oncology Center of Excellence, has been a specialty pharmacist at Lumicera since 2023. For the past two years, she has also been a caregiver for a cancer patient…her son.

Learn more about their unique journey:

Read their story

NAVITUS | 2024 Drug Trend Report

NAVITUS | 2024 Drug
Trend Report

Download the
Drug Trend Report
Executive Summary

Download the summary

Download the
Full Drug Trend
Report

Download the full report

I’d like the latest updates from Navitus

Sign me up

Methodology

The Navitus drug trend is calculated by comparing the net total cost PMPM for 2024 to that for 2023. Net cost PMPM represents full-year (Q1-Q4) data for total member copays and plan paid amounts, minus manufacturer rebates and fees. This value is divided by the total number of members and by 12 months of the year.
 
Net total cost PMPM trend consists of two components ­— utilization and cost ­— and includes both specialty and non-specialty drugs. Utilization trend measures the change in total days of therapy. Cost trend measures the change in net total drug cost per day of therapy. This analysis included data for more than 600 clients, representing 3.4M members within Navitus’ commercial book of business, including employer plan sponsors and health plans. To be included, these organizations must have been clients of Navitus in both 2023 and 2024. Exclusions from this analysis include products administered at physicians’ offices, clinics and hospitals, products subsidized by the federal government (i.e. COVID-19 vaccines/treatments), products excluded by benefit design (weight loss, infertility) and any additional savings from copay assistance programs.